Leveraging dPCR for residual DNA and viral titer quantitation in advanced therapy manufacture

Wednesday 08:00 PDT / 11:00 EDT / 16:00 BST / 17:00 CEST

Sponsor

Leveraging dPCR for residual DNA and viral titer quantitation in advanced therapy manufacture

Live30 webinars are thirty-minute presentations designed to update you on the latest innovations, applications, and data in a fast yet interactive format.

Leveraging digital PCR-based assays for the quantitation of residual host cell DNA or viral titers within a biotherapeutic manufacturing workflow offers significant value in ensuring product quality and safety. Digital PCR, or dPCR, is a highly sensitive and precise technique that enables the absolute quantification of nucleic acid targets. In the context of biotherapeutic manufacturing, dPCR provides a robust and accurate method for measuring residual host cell DNA or viral titers, which are critical parameters to assess the purity and potency of biopharmaceutical products. By employing dPCR-based assays, manufacturers can effectively monitor and control the levels of impurities, ensuring compliance with regulatory guidelines and minimizing the risk of adverse effects in patients. Additionally, dPCR's ability to detect low copy numbers and its resistance to PCR inhibitors make it a great analytical tool for biopharma. Overall, leveraging digital PCR-based assays enhances the efficiency, reliability, and quality of biotherapeutic manufacturing workflows, contributing to the development of safe and effective biopharmaceutical products.

How to enhance the sensitivity and accuracy of host cell DNA or viral titer quantitation within a biotherapeutic manufacturing workflow
Ensuring regulatory compliance in process impurity testing
Achieving an integrated workflow to support process development and a CGMP environment

Maya Dubey

Scientific Content Manager at Thermo Fisher Scientific

Maya Dubey is a Scientific Content Manager within the Pharma Analytics group at Thermo Fisher Scientific. She develops technical materials for both print and digital platforms. Prior to this role, Maya has gained extensive experience in the life science industry, holding various marketing positions as well as working as a research scientist specializing in cell and tissue culture. Maya holds a PhD in Biomedical Engineering and Biotechnology from the University of Massachusetts, where her doctoral dissertation focused on the impact of various proteins on neuronal growth and stability.